Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a clinical study titled ‘Low Interventional ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

Pfizer reported a jump in second-quarter profits Tuesday behind higher sales of Covid-19 products and some other ...

Pfizer bucked the trend of a tepid big pharma Q2 window, raising its full-year profit forecast on the back of strong sales ...

US mRNA specialist Moderna has announced that the UK Court of Appeal has upheld the validity of its EP'949 patent.